NASDAQ: TRAXFirst Tracks Biotherapeutics Inc Stock
$37.37+0.50 (+1.36%)
Updated Jul 21, 2026
First Tracks shares are trading... find out Why TRAX Price Moved with a free WallStreetZen account
Why Price MovedTRAX Price
$37.37
Fair Value Price
$6.45
Market Cap
$1.30B
52 Week Low
$14.88
52 Week High
$42.80
P/E
N/A
P/B
5.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
N/A
Beta
3.27
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TRAX Overview
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRAX
Ranked#97 of 464
Ranked#97 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important TRAX news, forecast changes, insider trades & much more!
TRAX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRAX ($37.37) is overvalued by 479.5% relative to our estimate of its Fair Value price of $6.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRAX ($37.37) is not significantly undervalued (479.5%) relative to our estimate of its Fair Value price of $6.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more TRAX due diligence checks available for Premium users.
Valuation
TRAX fair value
Fair Value of TRAX stock based on Discounted Cash Flow (DCF)
Price
$37.37
Fair Value
$6.45
Overvalued by
479.50%
TRAX ($37.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRAX ($37.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.06x
Industry
5.42x
TRAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRAX's financial health
Profit margin
Revenue
$0.0
Net Income
-$50.5M
Profit Margin
0%
Assets to liabilities
Assets
$290.6M
Liabilities
$33.1M
Debt to equity
0.13
TRAX's short-term assets ($289.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAX's short-term assets ($289.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.6M
Investing
$35.0M
Financing
$7.9M
TRAX vs Biotech Stocks
First Tracks Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.